TARGOBIOTICS™

The increasing incidence of antibiotic resistance and the severe shortage in new antibiotics have resulted in a considerable demand for new approaches against life-threatening bacterial infections. Rodos Biotarget’s TargoBiotics™ will help alleviate this demand.

targobiotics

TargoBiotics™ is composed of the CLR-TS with an encapsulated payload of different antibiotics. By reformulating and repurposing generic antibiotics and by partnering innovative antibiotics, TargoBiotics™ variants can deliver high antibiotic concentrations to sites of infection of the affected cell species. Currently, antibiotic concentrations for treating intracellular pathogens are often sub-therapeutic, resulting in the need for higher doses needed for therapeutic control.

In contrast, TargoBiotics™ enables control of the drug’s pharmacokinetic behavior, with reduced systemic toxicity, decreased emergence of resistance, and the reduction of overall treatment times.
This is costly and also associated with an increasing incidence of side effects to the antibiotic drugs. In contrast, TargoBiotics™ enables control of the drug’s pharmacokinetic behavior, with reduced systemic toxicity, decreased emergence of resistance, and the reduction of overall treatment times.

Rodos Biotarget currently is developing TargoBiotics™ against pathogens such as Listeria spec., Brucella spec., Mycobacterium tuberculosis, and Legionella pneumophilia, the causative agents of listeriosis (clinically manifested as sepsis and meningitis), brucellosis (Mediterranean Fever), multiresistant tuberculosis, and Legionnaires’ disease.

 
Back To Top